In vivo Inhibition of Human Platelet Function by VK 744

Abstract

VK 744 — a dipyridamole analogue — is an inhibitor of primary aggregation of platelets in vitro. In this paper we describe the in vivo effects in human male volunteers. A dose of 1500 mg VK 744 prolonged the kaolin‐stypven time and inhibited ADP aggregation. Administration of 500 mg three times daily during 48 hrs in a paired coded investigation produced a slightly significant prolongation of the kaolin‐stypven time. Side effects prevented continuation of the trial. The inhibition by indomethacin was not enhanced by combination with VK 744.